| P50 | author | David A Reardon | Q73570385 |
| | Evanthia Galanis | Q88613246 |
| P2093 | author name string | Howard Colman | |
| | Daniel Sargent | |
| | Jann Sarkaria | |
| | Susan M Chang | |
| | Wenting Wu | |
| P2860 | cites work | Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 |
| | MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 |
| | Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 |
| | MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. | Q27851529 |
| | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 |
| | Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 |
| | Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. | Q33186142 |
| | Clinical trial designs for predictive marker validation in cancer treatment trials | Q33213015 |
| | Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...] | Q33247166 |
| | Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. | Q33407127 |
| | Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? | Q33538461 |
| | A multigene predictor of outcome in glioblastoma. | Q34132666 |
| | A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma | Q34574621 |
| | Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma | Q35800632 |
| | Bayesian clinical trials | Q36399554 |
| | Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines | Q37216709 |
| | Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers | Q40923195 |
| | Statistical aspects of prognostic factor studies in oncology | Q42388377 |
| | NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 |
| | Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas | Q44768519 |
| | Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. | Q45918451 |
| | Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. | Q48493738 |
| | Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. | Q53883940 |
| | Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. | Q54714055 |
| | Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. | Q55476212 |
| | Issues and barriers to development of clinically useful tumor markers: a development pathway proposal | Q74296025 |
| | A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer | Q80808476 |
| P433 | issue | 1 | |
| P921 | main subject | brain tumor | Q233309 |
| | biomarker | Q864574 |
| P304 | page(s) | 42-49 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments | |
| P478 | volume | 13 | |